A5054372225- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Chromatin Remodeling and Cancer
- Cervical Cancer and HPV Research
- Intraperitoneal and Appendiceal Malignancies
- Cancer Immunotherapy and Biomarkers
- Uterine Myomas and Treatments
- Cancer Mechanisms and Therapy
- PARP inhibition in cancer therapy
- Endometriosis Research and Treatment
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Palliative Care and End-of-Life Issues
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Economic and Financial Impacts of Cancer
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Cancer survivorship and care
- Mechanisms of cancer metastasis
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Epigenetics and DNA Methylation
University of Virginia
2016-2025
University of Virginia Cancer Center
2019-2025
University of Virginia Health System
2013-2024
University of Virginia Medical Center
2012-2024
Charlottesville Medical Research
2019-2022
Beijing Obstetrics and Gynecology Hospital
2022
John Wiley & Sons (United States)
2019-2021
Hudson Institute
2019-2021
UNM Comprehensive Cancer Center
2021
University of New Mexico
2014-2021
Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding PD-L1 and PD-L2. We report interim data from patients endometrial cancer (EC) participating phase I trial single-agent dostarlimab. Methods GARNET, an ongoing, single-arm, open-label, intravenous dostarlimab advanced solid tumors, being undertaken at 123 sites. Two cohorts EC were recruited: those dMMR/MSI-H disease (cohort A1) proficient/stable (MMRp/MSS) A2)....
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in United States.We conducted phase 3, global, confirmatory, open-label, randomized, controlled trial to compare efficacy and safety MIRV with investigator's choice chemotherapy platinum-resistant, high-grade serous cancer. Participants who had previously received one three lines therapy high FRα tumor expression...
Abstract Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization inhibitor. We assessed safety, activity and pharmacokinetics of the combination AR/bevacizumab (Bev) (ARB) versus weekly paclitaxel (wP)/Bev (PB) patients platinum resistant/refractory HGOC (prrHGOC). Expiremental design: Following run-in phase I study to assess ARB prrHGOC...
BACKGROUND A reliable model for predicting the outcome of primary cytoreductive surgery may be a useful tool in clinical management patients with advanced epithelial ovarian carcinoma. METHODS Forty-one women preoperative computed tomographic (CT) scan abdomen and pelvis histologic diagnosis Stage III or IV carcinoma following performed by one nine gynecologic oncologists were identified from tumor registry databases. All CT scans analyzed retrospectively using panel 25 radiographic features...
The clinical and histopathologic features of 187 high-grade endometrial cancers [FIGO grade 3 endometrioid (EC-3), serous (SC), clear cell (CC)] were studied to determine whether clinicopathologic differences between these various histologic subtypes existed. study group consisted 89 EC-3s, 61 SCs, 37 CCs. Treatment regimens individualized. SCs CCs significantly more likely than EC-3s occur in patients older 65 years (P=0.03), tended frequently African descent (P=0.07), although this was not...
<h3>Objectives</h3> Abdominal radical trachelectomy (ART) is a type C resection (uterine vessels ligated at origin from the hypogastric vessels). Questions arise as to whether fertility maintained after ART, particularly when uterine are sacrificed. We report an international series on ART describe and oncologic outcomes. <h3>Methods</h3> Databases 3 institutions were queried identify patients planned for 1999 2011. Clinical demographic data gathered. <h3>Results</h3> One hundred one...
Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified data on post-immunotherapy progression are lacking. We explored the combination of checkpoint inhibitor (nivolumab) an agent (cabozantinib) immunotherapy-naïve cancer patients whose disease progressed previous with baseline biopsy immune profiling.In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11,...
Abstract Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin remodeling complex subunit ARID1A occur frequently advanced urothelial, endometrial, and ovarian clear cell carcinomas, creating an alternative state that may be exploited therapeutically. The histone methyltransferase EZH2 has been previously identified as targetable vulnerability context of mutations. In this study, we describe discovery tulmimetostat, orally available, clinical stage inhibitor, it...
Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought confirm proportion patients with at least 1 actionable alteration whether use molecularly targeted was associated improved survival metastatic cancer. A multidisciplinary consortium formed study treatment therapies Tumor therapeutic decisions were physician's recommendations. The abstracted data included age, stage,...
In vitro work suggests that cytokines may be important modulators of the cytotoxic effects paclitaxel and subsequent drug resistance. This has been investigated in vivo patients with ovarian cancer by ELISA. There was consistently elevated expression IL-6 IL-8 but not MCP-1, IL-1beta, IL-2, GM-CSF or TNFalpha. Peritoneal fluid concentrations IL-6, MCP-1 were two to three logs greater than serum concentrations. Elevated correlated a poor final outcome (P = 0.039), increased initial response...
Despite advances in radical surgery and chemotherapy delivery, ovarian cancer is the most lethal gynecologic malignancy. Standard therapy includes treatment with platinum-based combination chemotherapies yet there no biomarker model to predict their responses these agents. We here have developed independently tested our multi-gene molecular predictors for forecasting patients' individual drugs on a cohort of 55 patients. To validate predictors, we performed microarray profiling FFPE tumor...